Table 1 Patient characteristics
From: Brachytherapy for targeting the immune system in cervical cancer patients
Number (%) | |
|---|---|
Number of patients | 19 (100) |
Age, years [mean(range)] | 55.9 (40–74) |
FIGO stage 1 | |
IB1 | 1 (5.3) |
IB2 | 1 (5.3) |
IIA | 3 (15.8) |
IIB | 7 (36.8) |
IIIA | 3 (14.8) |
IIIB | 4 (21.0) |
Histopathology | |
Squamous cell carcinoma | 17 (89.5) |
Adenocarcinoma | 1 (5.3) |
Mucinous carcinoma | 1 (5.3) |
Tumor differentiation grade | |
Well-differentiated | 3 (15.8) |
Moderately differentiated | 10 (52.6) |
Poorly differentiated | 6 (31.6) |
Human papillomavirus (HPV) infection | 19 (100) |
External beam radiation therapy | 19 (100) |
Brachytherapy | |
HDR | 7 (36.8) |
PDR | 12 (63.2) |
Platinum-based chemotherapy | |
Yes | 18 (94.7) |
No | 1 (5.3) |
Lymphadenectomy | |
Yes | 7 (36.8) |
No | 12 (63.2) |